<DOC>
	<DOCNO>NCT02613507</DOCNO>
	<brief_summary>The purpose study determine whether Nivolumab improve life expectancy compare Docetaxel Subjects Advanced Metastatic Non-small Cell Lung Cancer fail prior platinum-based doublet chemotherapy .</brief_summary>
	<brief_title>Efficacy Study Nivolumab Compared Docetaxel Subjects Previously Treated With Advanced Metastatic Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Disease progression experience one prior platinum contain doublet chemotherapy Stage IIIb/IV recurrent disease Male Female ≥ 18 year age Measurable disease per RECIST 1.1 Performance Status ≤ 1 History Carcinomatous meningitis Active Central nervous system ( CNS ) metastases History auto immune diseases Prior treatment Docetaxel Prior treatment ipilimumab drug target TCell costimulation checkpoint pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>